Nobuyuki Tajima

Summary

Affiliation: Japan Tobacco Inc
Country: Japan

Publications

  1. ncbi Critical role of activation-inducible lymphocyte immunomediatory molecule/inducible costimulator in the effector function of human T cells: a comparative in vitro study of effects of its blockade and CD28 blockade in human beings and monkeys
    Nobuyuki Tajima
    Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Takatsuki, Osaka, Japan
    Hum Immunol 69:399-408. 2008
  2. ncbi JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs
    Nobuyuki Tajima
    Biological and Pharmacological Laboratories Central Pharmaceutical Research Institute, Takatsuki, Japan
    Exp Hematol 36:1514-23. 2008
  3. ncbi Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide
    Takayuki Yamaguchi
    Central Pharmaceutical Research Institute, Japan Tobacco Inc, Murasaki cho, Takatsuki, Osaka, Japan
    Inflamm Res 61:445-54. 2012
  4. ncbi JTE-607, a multiple cytokine production inhibitor, induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells
    Nobuyuki Tajima
    Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan
    Cancer Sci 101:774-81. 2010
  5. ncbi JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model
    Naofumi Uesato
    Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan
    Exp Hematol 34:1385-92. 2006
  6. ncbi Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo
    Takayuki Yamaguchi
    Central Pharmaceutical Research Institute, Japan Tobacco Inc, Takatsuki, Osaka 569 1125, Japan
    Int J Oncol 39:23-31. 2011

Collaborators

Detail Information

Publications6

  1. ncbi Critical role of activation-inducible lymphocyte immunomediatory molecule/inducible costimulator in the effector function of human T cells: a comparative in vitro study of effects of its blockade and CD28 blockade in human beings and monkeys
    Nobuyuki Tajima
    Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Takatsuki, Osaka, Japan
    Hum Immunol 69:399-408. 2008
    ....
  2. ncbi JTA-009, a fully human antibody against human AILIM/ICOS, ameliorates graft-vs-host reaction in SCID mice grafted with human PBMCs
    Nobuyuki Tajima
    Biological and Pharmacological Laboratories Central Pharmaceutical Research Institute, Takatsuki, Japan
    Exp Hematol 36:1514-23. 2008
    ..In the present study, the role of human AILIM/ICOS in T-cell function was investigated using a fully human monoclonal antibody specific to human AILIM/ICOS (JTA-009)...
  3. ncbi Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide
    Takayuki Yamaguchi
    Central Pharmaceutical Research Institute, Japan Tobacco Inc, Murasaki cho, Takatsuki, Osaka, Japan
    Inflamm Res 61:445-54. 2012
    ..To examine the effects of a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2-inhibitor, JTP-74057, on inflammatory arthritis development, and compare its anti-arthritic effect with leflunomide...
  4. ncbi JTE-607, a multiple cytokine production inhibitor, induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells
    Nobuyuki Tajima
    Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan
    Cancer Sci 101:774-81. 2010
    ..These results suggest the usefulness of JTE-607 in therapeutic applications for patients with hypercytokinemia and aggressive AML cell proliferation...
  5. ncbi JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model
    Naofumi Uesato
    Biological and Pharmacological Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, Japan
    Exp Hematol 34:1385-92. 2006
    ..In the present study, we investigated the potency of JTE-607 as an antileukemic agent by exploiting a SCID mouse acute leukemia model...
  6. ncbi Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo
    Takayuki Yamaguchi
    Central Pharmaceutical Research Institute, Japan Tobacco Inc, Takatsuki, Osaka 569 1125, Japan
    Int J Oncol 39:23-31. 2011
    ..These results suggest the usefulness of JTP-74057 in therapeutic applications for colorectal cancer patients...